Maria Sharapova ‘never doubted’ tennis career would continue

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Maria Sharapova of Russia serves in her Ladies' Singles Fourth Round match against Zarina Diyas of Kazakhstan during day seven of the Wimbledon Lawn Tennis Championships at the All England Lawn Tennis and Croquet Club on July 6, 2015 in London, England. (Photo by Shaun Botterill/Getty Images)

(CNN) — Maria Sharapova always knew her drugs ban would not be the way her tennis career would end.

The five-time grand slam champion will return to the sport in April 2017 after serving a 15-month suspension for testing positive for the banned substance meldonium at the Australian Open in January.

Sharapova was initially banned for two years by the International Tennis Federation (ITF), but the Court of Arbitration for Sport (CAS) reduced the sanction by nine months, saying she bore “no significant fault or negligence.”

The panel concluded that while she did commit a doping violation, she was not an “intentional doper.”

“I knew this was never the way I going to finish my career and I was going to do it on my terms… I never doubted that,” Sharapova told CNN.

The 29-year-old Russian added: “I know who I am and I know how I’ve played the sport since I was a young girl, with integrity, I’ve never taken the easy way out, I’m one of the biggest fighters in the game.

“I love what I do and I will continue to keep doing it and forming with my legacy.”

Sharapova said she was first prescribed the drug, also known as mildronate, in 2006 for heart issues and was unaware it had been added to the banned substance list by the World Anti-Doping Agency (WADA) as of January 1.

An independent panel appointed by the ITF ruled Sharapova hadn’t used meldonium as a vehicle for cheating but stated the former world No. 1 was “the sole author of her misfortune” and handed out the two-year ban.

However, Sharapova’s legal team argued to CAS that she simply failed to read an email that stated meldonium would be added to the banned list. Her IMG agent Max Eisenbud also failed to check, it said.

Sharapova’s lawyer, John Haggerty, called Tuesday’s ruling a ”stunning repudiation” of the ITF, which he said failed to properly notify players of the meldonium ban.

The International Tennis Federation told CNN in a statement Wednesday: “We have reviewed, and will continue to review, our processes for communicating changes to the Prohibited List to players with the aim of ensuring that no player can claim that they had not been fully informed.”

Sharapova’s sponsor and racquet manufacturer Head tweeted its congratulations Tuesday, saying it was “proud to have stood by Maria for the right reasons throughout these difficult times.”

The comment drew an adverse reaction on social media, but Head chief executive Johan Eliasch stood by the sentiment.

“In this case there is absolutely no evidence that meldonium, which is the substance Maria took, is actually a performance enhancer as highlighted by the fact there was no clinical testing performed by Wada which is weird, to say the least,” Sweden’s Eliasch told CNN.

“No-one likes cheating in sport and that should be eradicated — people who do that should face very severe consequences — but in this case it is so abundantly clear it’s not about cheating, it is an honest mistake.”

Eliasch suggested Sharapova’s treatment could be part of an anti-Russian reaction.

“I would also like to add apparently the substance was banned because of the prevalence of meldonium use by eastern European athletes. Maybe this has a bit of an element of Russia bashing. I don’t think politics and sport should be mixed up,” he said.

WADA is yet to respond to CNN’s request for comment on Eliasch’s allegation.

Sharapova was valued as the world’s richest female athlete for 11 straight years until she was unseated by Serena Williams this year.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.